Neurona Therapeutics to Launch Phase 3 Trial for NRTX-1001 in Drug-Resistant Epilepsy

Neurona Therapeutics has announced the launch of its Phase 3 EPIC trial for NRTX-1001, a groundbreaking cell therapy for drug-resistant epilepsy. This pivotal trial, set to begin in late 2025, will assess the safety and efficacy of NRTX-1001 in patients with mesial temporal lobe epilepsy (MTLE), the most common form of adult epilepsy. Unlike traditional surgical treatments, which can impair memory and cognition, NRTX-1001 offers a regenerative, tissue-sparing approach aimed at restoring brain function. Early trials have demonstrated promising results, with significant seizure reduction and no reported cognitive side effects.

Supported by an RMAT designation from the FDA, NRTX-1001 has shown a 92% median seizure reduction in low-dose patients and a 78% reduction in high-dose recipients. Some patients experienced over 97% seizure reduction lasting 24 months after a single dose. "This milestone represents a major step forward for epilepsy treatment," said CEO Cory R. Nicholas, Ph.D. If successful, this therapy could provide a revolutionary alternative for patients with drug-resistant epilepsy, potentially reshaping the future of neurological care.